Revivo’s development team is composed of experienced drug development professionals, each with greater than 25 years of experience in large pharma and small pharma settings. Most recently this team successfully developed and licensed therapies for Cardioxyl Pharmaceuticals.

 
 
 

John Reardon, PhD

Chief Scientific Officer


28 years of biopharmaceutical research and pre-clinical development experience


Held positions at GlaxoSmithKline, Glaxo Wellcome, Burroughs-Wellcome, Integrated Oncology Solutions


Head of global discovery biology at GSK, leading a team of >600 working across all therapeutic areas


Past CSO at Cardioxyl

Doug Cowart, Pharm D

President and CEO


Extensive experience in corporate development, strategy and financing


30 years of clinical development experience


Led early clinical programs at Otsuka, Sigma Tau, Cardiome, Nitromed, Cortria, and Cardioxyl


COO at multispecialty CRO-Medifacts


Board Certified in Clinical Pharmacology and Regulatory Affairs


Past EVP Development & Regulatory at Cardioxyl

Vince Kalish, PhD

SVP Chemistry & Preclinical Development


28 years of experience in biopharma research and development of drug candidates


Held positions at Guilford, Agouron, Idun, GD Searle, Cardioxyl


Successful research, chemistry and project leader to clinical candidates and marketed drugs


Past SVP Chemistry & IP at Cardioxyl

Doris Cully, PhD

VP Molecular Pharmacology &
Preclinical Development


29 years of biopharmaceutical research and pre-clinical development experience


Held positions at Merck & Co and Cardioxyl


Directed early discovery and pre-clinical programs in multiple therapeutic areas


Past VP Molecular Pharm & Preclinical Development at Cardioxyl

Craig Hartman, PhD

VP Pharmacology & Development


30 years of biopharmaceutical research and pre-clinical development experience.


Held positions at American Hospital Supply, Baxter , Pharmacia Upjohn, Somatogen, Myogen, Gilead, Cardioxyl


Extensive experience in preclinical discovery/development; led preclinical teams from IND enabling through post-marketing


Past VP Pharmacology/Toxicology & Preclinical Development at Cardioxyl

Robert Venuti, BA

VP Clinical Development


29 years of clinical development experience


Held positions at SmithKline & French/SmithKline Beecham Sphinx, Intercardia, TransTech, Entegrion, Tranzyme


Past Sr. Director Clinical Development at Cardioxyl